Charles River Laboratories International, Inc. provided earnings guidance for the full year of 2022. For the year, the company expects revenue growth in the range of 13.0% to 15.0% and GAAP EPS estimate in the range of $9.20 $9.45.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
226.8 USD | -0.34% | -3.88% | -4.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.07% | 11.68B | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
+21.36% | 11.6B | |
+8.20% | 11.15B | |
-19.49% | 9.78B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year of 2022